Supplementary figure 1

Aug 09, 2014

20 likes | 92 Vues

A. Pkb a +/+ Pkb a -/-. C1 C2. PKB b. muscle. actin. PKB b. fat. actin. PKB b. liver. actin. Pkb a +/+. 125. Pkb a -/-. 100. 75. PKB b protein expression [% of control]. 50. 25. B. 0. muscle. fat. liver. 125. 100. 75. Pkb mRNA expression

Share Presentation

Embed Code

Link

pkbb fat
pkba pkbg supplementary
c2 pkbb
muscle actin
actin pkbb
pkbg pkbb supplementary

piera

Télécharger la présentation

Supplementary figure 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

A Pkba+/+ Pkba-/- C1 C2 PKBb muscle actin PKBb fat actin PKBb liver actin Pkba+/+ 125 Pkba-/- 100 75 PKBb protein expression [% of control] 50 25 B 0 muscle fat liver 125 100 75 Pkb mRNA expression in islets [% of control] 50 25 0 Pkbg Pkbb Supplementary figure 1
150 100 Pkb mRNA expression in islets [% of control] Pkbb+/+ 50 Pkbb-/- 0 Pkba Pkbg Supplementary figure 2

Supplementary figure 1

Supplementary figure 1. Supplementary figure 2 . sNF96.2. ST88-14. T265-2C. NF90.8. Supplementary figure 3. NF90.8. sNF96.2. T265-2C. ST88-14. Supplementary figure 4. A. B. NF90.8. siRNA mTOR#13. siRNA mTOR#19. siRNA GFP. mTOR. GAPDH. ST88-14. siRNA mTOR#13.

210 views • 12 slides

Supplementary Figure 1

Supplementary Figure 1. MW/1000. pH. SJIA. POLY. Others. F. FI. F. KD. Q. Q. C3. AGP1. ACT. SAP. SAA. S100A8. S100A9. HP. CRP. C9. C4. APO-IV. APO-L1. AMBP. KLKB1. VDB. CFH. ATIII. A2M. ATIII. APO-E. APO-D. FGG FGB. TTR. GSN. APOA1. Figure 1. 12. 10. 8.

182 views • 7 slides

Supplementary Figure 1

Supplementary Figure 1. A. B. C. Supplementary Figure 2. Supplementary Figure 3. A. PHTX-14B Day 10. B. MDA-MB-231 Day 10. Supplementary Figure 4. Vehicle. MLN8237 20mg/kg QDx3/wk. Treatment Period. 2500. 2000. 1500. Average Tumor Volume (mm^3). 1000. 500. 0. 0. 10. 20.

249 views • 5 slides

Supplementary Figure 1

Supplementary Figure 1. 3. 2,5. 2. 1,5. 1. 0,5. 0. 6. 5. 4. 3. 2. 1. 0. A. WT with FSK+Gen. WT with FSK. lF508del with FSK+Gen. lF508del with FSK. ns. ns. ns. ns. Bicarbonate secretion ( normalized to the rate in FSK-treated F508del as 1). 10 min post peak response.

107 views • 2 slides

Supplementary Figure 1

Supplementary Figure 1. a. b. c. a continuous schedule for 35 consecutive days. an intermittent schedule. DNA vaccination (50 ug/mouse). DNA vaccination (50 ug/mouse). A20 Lymphoma. A20 Lymphoma. Day. Day. 1. 35. 0. 14. 28. 0. 14. 28. 42. 21. 18. 35. 42. 32. 7. 4.

97 views • 3 slides

Supplementary Figure 1

a. *. *. ns. 3. 2. RANK Arbitrary Score. 1. 0. b. RANK. 1 2 3 4 5 6 7 8 9 10 11. Metastasis lymph node. Primary tumor. Normal breast. Supplementary Figure 1. Prolactin. RANKL. RANKL. pERK1/2. pERK1/2. pAKT. ERK1/2. AKT. b -Actin. pSTAT5. STAT5.

164 views • 7 slides

Supplementary Figure 1

Supplementary Figure 1. HM466934. I. II. pre-A. A. B. C. D/E. Supplementary Figure 2. V. IV. HM466934. HM466934. VI. HM466934. Supplementary Figure 3. HM466935. CDUV. Supplementary Figure 4. 34. MRMBV. MRCV. TUAV. ORXV. ALEV.

166 views • 4 slides

Supplementary Figure 1

IgVH unmutated. IgVH mutated. Low-risk. Intermediate-risk. High-risk. P14 cluster. N6 cluster. ZAP-70. CD38. IgVH status. Supplementary Figure 1.

81 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. CEPH: CYP2C8 (40kb, chr10:96782845..96822844). MAF=0.05. B. Hap-B. Hap-E. Hap-F. Haplotypes above 2%. Hap-A. Hap-D. Hap-C1+C2. Hap-C3. 3´UTR. CYP2C8. Pr. A. JPT+HCB: Asian. YRI: African. Supplementary Figure 2. A. B. C. A. B. C. Hap D (*3). Hap B.

199 views • 3 slides

Supplementary Figure 1

A. B. D. C. E. CD20. CagA. Merge. DAPI. Supplementary Figure 1.

168 views • 2 slides

Supplementary Figure 1

Nephrin. Nephrin. Nephrin. Nephrin. Nephrin. Synaptopodin. Synaptopodin. Synaptopodin. Synaptopodin. Synaptopodin. A. Merge. Merge. Merge. Merge. Merge. B. Podocin. Podocin. Podocin. Podocin. Podocin. Day 28. Control. Day 3. Day 15. Day 7. ADRN 11 mg/kg. Cont. Day3.

65 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. A. MIG (pMSCV-ires-GFP). I. GFP. LTR. LTR. MIG-PL2 (pMSCV-PLAGL2-ires-GFP). PL2. GFP. LTR. LTR. I. B. CBFb-MYH11 + HPs. GFP sort. Gene expression profile. Genes commonly deregulated in PL2+ cells. MIG-PL2 transduction. MIG transduction. GFP sort.

124 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. A. B. C.

72 views • 1 slides

Supplementary Figure 1.

MgrA. MepR. Supplementary Figure 1.

64 views • 1 slides

Supplementary Figure 1

90. 85. 80. 75. 70. 65. 40. 44. 48. 52. 56. 90. 80. 70. 60. 50. 38. 40. 42. 44. 46. 48. 50. 52. 90. 80. 70. 60. 50. 40. 30. 25. 30. 35. 40. 45. 50. 55. Normal. r = 0.043. p = 0.678. Methylation Level of LINE1 (%). Background. r = 0.063. p = 0.559.

87 views • 3 slides

Supplementary Figure 1

Supplementary Figure 1. Nominal p-value =0.0 FDR q-value= 0.19. Nominal p-value =0.004 FDR q-value= 0.30. Nominal p-value =0.013 FDR q-value= 0.19. Nominal p-value =0.033 FDR q-value= 0.18. Nominal p-value = 0.007 FDR q-value= 0.18. Nominal p-value =0.075 FDR q-value= 0.19.

114 views • 5 slides

Supplementary Figure 1

Supplementary Figure 1. Venkatachalam et al. 2013. ab. a. ab. abc. c. 24 48 72 96 120. Hours after FB17 treatment. Supplementary Figure 2. Venkatachalam et al. 2013. At1g11610. At3g28360. At1g21240. At3g14460. At3g20190. UBQ1.

137 views • 4 slides

Supplementary Figure 1

Supplementary Figure 1. Expansion of MSCs in 20% oxygen vs 5% oxygen. Supplementary Figure 2. Expansion of Kaneka-filtered cells in Flasks (P4) and the Quantum (P2). Supplementary Figure 3. Adipogenesis. Osteogenesis. Chondrogenesis.

251 views • 8 slides

Supplementary Figure 1

65 views • 2 slides

Supplementary Figure 1

Supplementary Figure 1. ***. 120000. 100000. ***. 80000. 60000. Relative light units (RLU). 40000. 20000. 0. Dox. +. -. +. -. Line I. Line 2. rtTA. rtTA. A. MMTV- rtTA TET0-PELP1 Line 1. MMTV- rtTA TET0-PELP1 Line 2. B. TetO-PELP1. MMTV- rtTA. WT. + Dox. T7-PELP1.

101 views • 1 slides

Supplementary Figure 1

A. *. A average weight [g]. A average weight [g]. CR. CR. Control. Control. T ime of experiment [week s ]. T ime of experiment [week s ]. *p<0,05. B. Supplementary Figure 1.

67 views • 1 slides

Supplementary Figure 1.

75 views • 1 slides

More Related